Abstract:Nimodipine is a 1,4-dihydropyridine-derivative Ca(2+)-channel blocker developed approximately 30 years ago. It is highly lipophilic, crosses the blood-brain barrier, and reaches brain and cerebrospinal fluid. Early treatment with nimodipine reduces the severity of neurological deficits resulting from vasospasm in subarachnoid haemorrhage (SAH) patients. In SAH, nimodipine reduced spasm-related deficits of all severities, but no spasm-unrelated deficits. This paper has reviewed preclinical studies on the influence of nimodipine in various animal models of cerebral ischemia, with particular attention toward investigations published in the last 10 years. These studies further support the main indication of nimodipine, by clarifying some mechanisms of the anti-ischemic activity of the compound. Papers reporting a possible role of nimodipine in epileptogenesis were also examined. Clinical studies on nimodipine were grouped into subarachnoid hemorrhage, acute ischemic stroke, cerebral ischemia without stroke, dementia disorders, and migraine. Clinical investigations have shown that the drug improves neurological outcome by reducing the incidence and severity of ischemic deficits in patients with SAH from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition. No relevant effects of treatment with nimodipine were reported for acute ischemic stroke, cerebral ischemia without stroke, and migraine, except than for cluster headache. The less pronounced cardiovascular effects of nimodipine compared to other dihydropyridine-type Ca(2+)-channel blockers probably accounts for its use out of label for treating patients affected by chronic cerebral ischemia and vascular cognitive impairment. However, the blood pressure-lowering effects of nimodipine should not be minimized, as clinical studies have documented lowering blood pressure in small groups of patients, including cases of withdrawn due to pronounced hypotension induced by nimodipine administration. In the area of vascular cognitive impairment, short-term benefits of nimodipine do not justify its use as a long-term anti-dementia drug, and benefits obtained in elderly patients affected by subcortical vascular dementia require to be confirmed by other groups and in larger scale trials. In conclusion, nimodipine is a safe drug with an important place in pharmacotherapy and with the main documentation for reduction in the severity of neurological deficits resulting from vasospasm in SAH patients.

Nimodipine Attenuates Early Brain Injury by Protecting the Glymphatic System After Subarachnoid Hemorrhage in Mice

The Efficacy and Safety of Nimodipine in Acute Ischemic Stroke Patients with Mild Cognitive Impairment: a Double-Blind, Randomized, Placebo-Controlled Trial

Nimodipine Reduces Microvasospasms After Experimental Subarachnoid Hemorrhage

Improvement Effect of Nimodipine on Brain Function in Rats with Subarachnoid Hemorrhage

Nimodipine attenuation of early brain dysfunctions is partially related to its inverting acute vasospasm in a cisterna magna subarachnoid hemorrhage (SAH) model in rats

Effects of Topical Administration of Nimodipine on Cerebral Blood Flow Following Subarachnoid Hemorrhage in Pigs.

Nimodipine inhibits spreading depolarization, ischemic injury, and neuroinflammation in mouse live brain slice preparations

Acute Effects of Nimodipine on Cerebral Vasculature and Brain Metabolism in High Grade Subarachnoid Hemorrhage Patients

Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis

Nimodipine Protects Vascular and Cognitive Function in an Animal Model of Cerebral Small Vessel Disease

Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage

The Therapeutic Effect of Nimodipine in Treatment of Severe Traumatic Brain Injuries with Subarachoid Hemorrhage

Investigating the therapeutic effects of nimodipine on vasogenic cerebral edema and blood-brain barrier impairment in an ischemic stroke rat model

Effects of nimodipine on nervous functions, ability of daily life and plasma neuron-specific enolase of patients with hypertensive cerebral hemorrhage

Naringenin Reduces Early Brain Injury in Subarachnoid Hemorrhage (SAH) Mice: the Role of the AMPK/SIRT3 Signaling Pathway

pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH

Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies

R-type calcium channels antagonist significantly improves cerebral blood flow following subarachnoid hemorrhage in rats

Clinical Study of Therapeutic Effect of Nimodipine on Traumatic Subarachnoid Hemorrhage

An experimental study of the effect of nimodipine in primate subarachnoid haemorrhage

Effects of dose-response of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits.